Every 10-Q that Citius Oncology, Inc. (CTOR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CTOR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CTOR filings page.
Citius Oncology, Inc. reported its first meaningful commercial period following the December 2025 launch of LYMPHIR, an immunotherapy for cutaneous T‑cell lymphoma. For the nine months ended June 30, 2026, LYMPHIR generated $7.1 million in revenue with about 77% gross profit, and total assets were $112.1 million, including $69.4 million of in‑process R&D and $22.6 million of inventory.
The company remains highly loss‑making, with a nine‑month net loss of $41.1 million, accumulated deficit of $105.1 million, and negative working capital of roughly $16.1 million. A former contract manufacturer terminated its agreement, triggering about $20.1 million of termination fees and a related $19.7 million contract cancellation charge.
Citius Oncology ended the quarter with $16.6 million in cash, supported by $9.7 million of warrant‑exercise proceeds and an up to $25.0 million secured term loan, of which $10.0 million has funded. Management expects existing resources, together with support from majority owner Citius Pharmaceuticals, to fund operations only through November 2026 and discloses substantial doubt about continuing as a going concern.
Citius Oncology reported its first meaningful commercial results for LYMPHIR while remaining deeply loss-making and liquidity‑constrained. For the six months ended March 31, 2026, net revenue reached $5,611,409, all from LYMPHIR, with gross margin of about 80%. However, the company posted a six‑month net loss of $32,143,764, including a $19,733,307 contract cancellation fee after its bulk drug‑substance CMO terminated production and the agreement. Quarterly net loss was $26,609,695.
At March 31, 2026, Citius Oncology held $2,632,634 in cash, inventory of $22,659,590, total liabilities of $65,430,399, and negative working capital of about $29.4 million, prompting a going concern warning. Subsequent events included roughly $11.5 million in warrant‑exercise proceeds and a Loan and Security Agreement providing up to $25.0 million of secured term loans maturing in 2029, but management still expects to need additional capital beyond November 2026.
Citius Oncology reported its first product revenue after launching LYMPHIR for cutaneous T‑cell lymphoma, generating $3.94M in the quarter ended December 31, 2025. Gross profit was about 80%, reflecting high-margin oncology sales.
The company still posted a net loss of $5.53M, narrower than a year earlier, and ended the quarter with $7.30M in cash and a working capital deficit of about $7.6M. A December equity financing raised net proceeds of $15.1M, but management only expects funding to last through May 2026 and discloses substantial doubt about its ability to continue as a going concern without additional capital. Citius also faces significant milestone and manufacturing payment obligations alongside ongoing stock-based compensation expenses.